Scientific Reports (Nov 2022)

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

  • Christine Durier,
  • Laetitia Ninove,
  • Maeva Lefebvre,
  • Anne Radenne,
  • Corinne Desaint,
  • Jacques Ropers,
  • Rebecca Bauer,
  • Said Lebbah,
  • Diane Carette,
  • Marie Lachatre,
  • Anne-Sophie Lecompte,
  • Dominique Deplanque,
  • Elisabeth Botelho-Nevers,
  • Anne Conrad,
  • Bertrand Dussol,
  • Zoha Maakaroun-Vermesse,
  • Giovanna Melica,
  • Jean-François Nicolas,
  • Renaud Verdon,
  • Jacques Kiladjian,
  • Paul Loubet,
  • Catherine Schmidt-Mutter,
  • Christian Dualé,
  • Séverine Ansart,
  • Stéphane Priet,
  • Axel Levier,
  • Diana Molino,
  • Louis-Victorien Vieillard,
  • Béatrice Parfait,
  • Jean-Daniel Lelièvre,
  • Eric Tartour,
  • Xavier de Lamballerie,
  • Odile Launay,
  • ANRS0002S CoviCompareP Group,
  • AP-HP CoviCompareM Group,
  • Biological resource centers,
  • Laboratories,
  • Trial coordination,
  • Sponsor,
  • Scientific Committee

DOI
https://doi.org/10.1038/s41598-022-24409-w
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Immune response induced by COVID-19 vaccine booster against delta and omicron variants was assessed in 65 adults (65–84 years old) early aftesr a first booster dose. An increase in SARS-CoV-2 neutralizing antibodies was shown in individuals not previously infected without evidence of an age-related effect, with lower increase in those infected before a single dose of primary vaccination. Of note, humoral response was observed only starting from the 5th day after the boost.